{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341240","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2026-08-10T11:20:14+00:00","discovered_at":"2026-08-10T11:25:00.430079+00:00","generated_at":"2026-08-10T11:25:06.161699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silence Therapeutics Q2 2026 net loss narrows to $12.3M; divesiran Phase 2 dosing complete","bullets":["Net loss $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025; cash $72.1M at June 30, 2026.","R&D expenses fell to $9.1M from $17.6M YoY, mainly due to zerlasiran Phase 3 readiness completion and lower personnel costs.","Divesiran Phase 2 SANRECO trial completed patient dosing in 48 phlebotomy-dependent PV patients; EHA 2026 data presented.","SLN312 (AZD1705) Phase 1 results from AstraZeneca collaboration presented at EAS 2026; favorable safety and dose-dependent lipid reductions.","Preclinical SLN365 (GPR146) and SLN098 (INHBE) programs on track for potential IND filings in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341240","json":"https://secwatch.observer/filing/0001193125-26-341240.json","markdown":"https://secwatch.observer/filing/0001193125-26-341240.md","text":"https://secwatch.observer/filing/0001193125-26-341240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/0001193125-26-341240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/d162225d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:25:06.161699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}